China · Delayed Price · Currency is CNY Cathay Biotech Statistics
Total Valuation
Cathay Biotech has a market cap or net worth of CNY 33.16 billion. The enterprise value is 28.05 billion.
| Market Cap | 33.16B |
| Enterprise Value | 28.05B |
Important Dates
The next estimated earnings date is Wednesday, April 22, 2026.
| Earnings Date | Apr 22, 2026 |
| Ex-Dividend Date | Aug 1, 2025 |
Share Statistics
Cathay Biotech has 720.66 million shares outstanding. The number of shares has increased by 10.81% in one year.
| Current Share Class | 720.66M |
| Shares Outstanding | 720.66M |
| Shares Change (YoY) | +10.81% |
| Shares Change (QoQ) | -1.89% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 14.74% |
| Float | 250.71M |
Valuation Ratios
The trailing PE ratio is 50.14 and the forward PE ratio is 50.56.
| PE Ratio | 50.14 |
| Forward PE | 50.56 |
| PS Ratio | 10.08 |
| PB Ratio | 1.56 |
| P/TBV Ratio | 1.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 79.32 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 33.51, with an EV/FCF ratio of -85.65.
| EV / Earnings | 47.18 |
| EV / Sales | 8.53 |
| EV / EBITDA | 33.51 |
| EV / EBIT | 56.27 |
| EV / FCF | -85.65 |
Financial Position
The company has a current ratio of 6.94, with a Debt / Equity ratio of 0.01.
| Current Ratio | 6.94 |
| Quick Ratio | 5.86 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.33 |
| Debt / FCF | -0.85 |
| Interest Coverage | 36.38 |
Financial Efficiency
Return on equity (ROE) is 3.09% and return on invested capital (ROIC) is 1.68%.
| Return on Equity (ROE) | 3.09% |
| Return on Assets (ROA) | 1.52% |
| Return on Invested Capital (ROIC) | 1.68% |
| Return on Capital Employed (ROCE) | 2.33% |
| Revenue Per Employee | 1.90M |
| Profits Per Employee | 342,627 |
| Employee Count | 1,735 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 1.78 |
Taxes
In the past 12 months, Cathay Biotech has paid 105.00 million in taxes.
| Income Tax | 105.00M |
| Effective Tax Rate | 15.81% |
Stock Price Statistics
The stock price has increased by +1.64% in the last 52 weeks. The beta is 0.55, so Cathay Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | +1.64% |
| 50-Day Moving Average | 49.40 |
| 200-Day Moving Average | 49.40 |
| Relative Strength Index (RSI) | 34.30 |
| Average Volume (20 Days) | 3,252,225 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cathay Biotech had revenue of CNY 3.29 billion and earned 594.46 million in profits. Earnings per share was 0.92.
| Revenue | 3.29B |
| Gross Profit | 1.01B |
| Operating Income | 507.43M |
| Pretax Income | 664.06M |
| Net Income | 594.46M |
| EBITDA | 846.01M |
| EBIT | 507.43M |
| Earnings Per Share (EPS) | 0.92 |
Balance Sheet
The company has 9.01 billion in cash and 279.23 million in debt, giving a net cash position of 8.73 billion or 12.11 per share.
| Cash & Cash Equivalents | 9.01B |
| Total Debt | 279.23M |
| Net Cash | 8.73B |
| Net Cash Per Share | 12.11 |
| Equity (Book Value) | 21.22B |
| Book Value Per Share | 24.98 |
| Working Capital | 9.84B |
Cash Flow
In the last 12 months, operating cash flow was 418.01 million and capital expenditures -745.46 million, giving a free cash flow of -327.46 million.
| Operating Cash Flow | 418.01M |
| Capital Expenditures | -745.46M |
| Free Cash Flow | -327.46M |
| FCF Per Share | -0.45 |
Margins
Gross margin is 30.65%, with operating and profit margins of 15.43% and 18.08%.
| Gross Margin | 30.65% |
| Operating Margin | 15.43% |
| Pretax Margin | 20.20% |
| Profit Margin | 18.08% |
| EBITDA Margin | 25.73% |
| EBIT Margin | 15.43% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.40, which amounts to a dividend yield of 0.87%.
| Dividend Per Share | 0.40 |
| Dividend Yield | 0.87% |
| Dividend Growth (YoY) | 110.52% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 53.00% |
| Buyback Yield | -10.81% |
| Shareholder Yield | -9.93% |
| Earnings Yield | 1.79% |
| FCF Yield | -0.99% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 20, 2022. It was a forward split with a ratio of 1.4.
| Last Split Date | Jul 20, 2022 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
Cathay Biotech has an Altman Z-Score of 9.29 and a Piotroski F-Score of 7.
| Altman Z-Score | 9.29 |
| Piotroski F-Score | 7 |